Literature DB >> 30043661

Dimethyl fumarate therapy suppresses B cell responses and follicular helper T cells in relapsing-remitting multiple sclerosis.

Rikke Holm Hansen1, Helene Højsgaard Chow1, Finn Sellebjerg1, Marina Rode von Essen1.   

Abstract

BACKGROUND: Dimethyl fumarate (DMF) is a disease-modifying therapy used for patients with relapsing-remitting multiple sclerosis (RRMS). B cells are important contributors to the pathogenesis of RRMS, where they regulate the inflammatory immune responses and participate in development of lesions in the central nervous system (CNS). The impact of DMF on B cell subpopulations remains incompletely understood.
OBJECTIVES: In this study, we evaluated the effects of DMF on B cell subpopulations and their effector functions.
METHODS: Blood from 21 DMF-treated and 18 untreated patients with RRMS was analyzed by flow cytometry.
RESULTS: We found that DMF reduces the frequency of circulating antigen-experienced B cells, a reduction likely related to a reduced frequency of follicular helper T (TFH) cells and an increased frequency of follicular regulatory T (TFR) cells. Studying the impact of monomethyl fumarate (MMF), the primary metabolite of DMF, on B cell effector function in vitro showed that MMF increased the frequency of transforming growth factor (TGF)-β-producing B cells and decreased the frequency of B cells secreting lymphotoxin (LT)-α, tumor necrosis factor (TNF)-α, interleukin (IL)-6, and to a lesser extent IL-10.
CONCLUSION: In summary, these data suggest an anti-inflammatory role of DMF and its metabolite MMF on the B cell compartment.

Entities:  

Keywords:  B cells; Multiple sclerosis; cytokines; dimethyl fumarate; follicular helper T cells

Mesh:

Substances:

Year:  2018        PMID: 30043661     DOI: 10.1177/1352458518790417

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  10 in total

1.  High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.

Authors:  Martin Diebold; Edoardo Galli; Andreas Kopf; Nicholas S R Sanderson; Ilaria Callegari; Pascal Benkert; Nicolás Gonzalo Núñez; Florian Ingelfinger; Stefan Herms; Sven Cichon; Ludwig Kappos; Jens Kuhle; Burkhard Becher; Manfred Claassen; Tobias Derfuss
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-26       Impact factor: 12.779

Review 2.  Dysregulation of β-Cell Proliferation in Diabetes: Possibilities of Combination Therapy in the Development of a Comprehensive Treatment.

Authors:  Natsuki Eguchi; Arvin John Toribio; Michael Alexander; Ivana Xu; David Lee Whaley; Luis F Hernandez; Donald Dafoe; Hirohito Ichii
Journal:  Biomedicines       Date:  2022-02-17

3.  Dimethyl Fumarate Reduces Oxidative Stress and Pronociceptive Immune Responses in a Murine Model of Complex Regional Pain Syndrome.

Authors:  Tian-Zhi Guo; Xiaoyou Shi; Wenwu Li; Tzuping Wei; Wade S Kingery; J David Clark
Journal:  Anesth Analg       Date:  2021-05-01       Impact factor: 6.627

Review 4.  Differential Effects of MS Therapeutics on B Cells-Implications for Their Use and Failure in AQP4-Positive NMOSD Patients.

Authors:  Jan Traub; Silke Häusser-Kinzel; Martin S Weber
Journal:  Int J Mol Sci       Date:  2020-07-16       Impact factor: 5.923

Review 5.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

6.  Optimal response to dimethyl fumarate is mediated by a reduction of Th1-like Th17 cells after 3 months of treatment.

Authors:  María José Mansilla; Juan Navarro-Barriuso; Silvia Presas-Rodríguez; Aina Teniente-Serra; Bibiana Quirant-Sánchez; Cristina Ramo-Tello; Eva María Martínez-Cáceres
Journal:  CNS Neurosci Ther       Date:  2019-05-07       Impact factor: 5.243

7.  Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19.

Authors:  Cara A Timpani; Emma Rybalka
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-26

Review 8.  Follicular Helper CD4+ T Cells, Follicular Regulatory CD4+ T Cells, and Inducible Costimulator and Their Roles in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis.

Authors:  Xue Zhang; Ruli Ge; Hongliang Chen; Maxwell Ahiafor; Bin Liu; Jinbo Chen; Xueli Fan
Journal:  Mediators Inflamm       Date:  2021-09-12       Impact factor: 4.711

9.  Gut Microbiome and Bile Acid Metabolism Induced the Activation of CXCR5+ CD4+ T Follicular Helper Cells to Participate in Neuromyelitis Optica Spectrum Disorder Recurrence.

Authors:  Xi Cheng; Luyao Zhou; Zhibin Li; Shishi Shen; Yipeng Zhao; Chunxin Liu; Xiaonan Zhong; Yanyu Chang; Allan G Kermode; Wei Qiu
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

10.  Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial.

Authors:  Helene Højsgaard Chow; Jacob Talbot; Henrik Lundell; Camilla Gøbel Madsen; Lisbet Marstrand; Theis Lange; Mie Reith Mahler; Sophie Buhelt; Rikke Holm Hansen; Morten Blinkenberg; Jeppe Romme Christensen; Per Soelberg Sørensen; Marina Rode von Essen; Hartwig Roman Siebner; Finn Sellebjerg
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.